Visão geral da empresa
A clinical-stage biotechnology entity based in Switzerland, Molecular Partners AG focuses on the design and development of ankyrin repeat protein therapeutics specifically targeting oncology diseases. The company operates within the broader healthcare sector, functioning inside the specialized biotechnology industry where innovation in protein-based treatments is critical for advancing cancer therapies. Molecular Partners AG currently maintains a market capitalization of $162.07M and employs a workforce of 134 individuals to support its research and development activities. The market cap figure of $162.07M, combined with the absence of reported revenue in the traditional sense, indicates that the company is valued primarily on its intellectual property and clinical pipeline rather than established commercial sales streams, reflecting a typical profile for entities in the early stages of drug development.
Saúde financeira
Molecular Partners AG reports a net income of $-61,651,000 and an EBITDA of $-54,538,000, while the trailing twelve-month revenue is not available as a positive figure in the current reporting. The significant disparity between the negative net income and the less negative EBITDA reveals a substantial cost structure dominated by non-cash expenses, likely including significant depreciation and amortization related to intangible assets or research infrastructure. The company's free cash flow stands at $-27,532,124, which signifies a continued consumption of cash reserves to fund ongoing clinical trials and operational expenditures without generating immediate cash returns. All three reported margins—gross margin, operating margin, and profit margin—are listed as 0.0%, indicating that the company has not yet achieved profitability from its current commercial activities or that reported figures do not reflect a positive earnings trajectory. The balance sheet shows a cash position of $93.06M against total debt of $3.64M, resulting in a debt-to-equity ratio of 4.54, which suggests a highly leveraged structure relative to equity, though the absolute debt burden is manageable given the cash on hand. The current ratio is recorded at 8.79, implying a robust ability to cover short-term liabilities with short-term assets despite the lack of traditional revenue streams. Return on Equity is -55.5% and Return on Assets is -26.6%, metrics that collectively reveal that management is currently deploying capital to generate losses rather than positive returns, a common characteristic for clinical-stage biotechs investing heavily in high-risk development phases.
Avaliação de valorização
The trailing P/E ratio is not available due to negative earnings, whereas the forward P/E is calculated at -1.64, a metric that implies future earnings are still projected to be negative or that valuation models rely on non-traditional metrics for this specific stage of development. The price-to-book ratio is 1.61, suggesting that the market values the company's equity at a premium of 61% over its book value, likely driven by the potential value of the MP0317 pipeline in Phase 2 clinical trials. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are not applicable or show a negative EV/EBITDA of -1.33, indicating that traditional sales-based or earnings-based multiples cannot currently value the enterprise effectively without positive cash generation. The stock price has fluctuated between a 52-week high of $5.36 and a 52-week low of $3.36, providing a trading range where the current valuation must be assessed against these historical volatility markers. The beta of 0.74 indicates that the stock's price volatility is lower than the broader market, suggesting a defensive characteristic often found in small-cap biotechnology stocks that may not move in lockstep with general market indices.
Growth & Income
Revenue growth and earnings growth year-over-year are not available for reporting, which precludes a direct comparison of whether earnings are growing faster or slower than revenue in the traditional sense of a mature company. As a non-dividend payer, Molecular Partners AG does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all generated cash or existing reserves to reinvest into its drug development pipeline rather than providing income to investors. The absence of a dividend payout aligns with the company's strategic focus on funding clinical trials for MP0317 rather than rewarding shareholders with current income, necessitating that investors rely on potential future equity appreciation rather than yield. The overall growth and income profile is defined by a high-risk, high-reward dynamic where capital is deployed for long-term clinical milestones rather than short-term income generation or stable revenue expansion.